Latest / CME Outfitters Medical Education / Riding the Waves of Obesity Science – A Multi-Pathway Rationale for the Next Therapeutic Current
Transcript
- 0:11SPEAKER_02: Hello, I'm Dr.
- 0:12SPEAKER_00: Robert Kushner.
- 0:13SPEAKER_00: I'd like to welcome you to Riding the Waves of Obesity Science.
- 0:17SPEAKER_00: This is the first of four CME snacks, and it's titled A Multipathway Rationale for the Next Therapeutic Current.
- 0:26SPEAKER_00: This activity is provided by CME Outfitters and is supported by an independent educational grant from Novel Nordisk, Incorporated.
- 0:35SPEAKER_00: After participating in today's activity, learners should be better able to identify obesity as a chronic progressive disease in need of long-term management.
- 0:45SPEAKER_00: Again, I'm Dr.
- 0:46SPEAKER_00: Robert Krishner.
- 0:47SPEAKER_00: I'm a professor emeritus at Northwestern University, Feinberg School of Medicine in Chicago, in the Departments of Medicine and Medical Education.
- 0:56SPEAKER_00: And I'm very pleased to welcome Dr.
- 0:58SPEAKER_00: Lee Kaplan, who I'll ask to introduce himself.
- 1:01SPEAKER_00: Welcome, Lee.
- 1:03SPEAKER_01: Well, thank you.
- 1:04SPEAKER_01: Thank you for uh inviting me to participate today.
- 1:07SPEAKER_01: I'm Lee Kaplan.
- 1:08SPEAKER_01: I'm a uh hepatologist, obesity medicine physician, and uh former molecular biologist, retired now from uh Mass General Hospital and Harvard Medical School.
- 1:19SPEAKER_01: And uh I am mostly interested these days in uh figuring out how we can uh uh scale obesity care uh to the magnitude of the problem that it is.
- 1:29SPEAKER_00: Thank you, Lee.
- 1:30SPEAKER_00: You know, I uh it's so great to have you here.
- 1:32SPEAKER_00: I really can't think of anyone better to start off this whole SNAC series and have kind of a wide lens when we talk about obesity.
- 1:41SPEAKER_00: And I want to start off with the really the main learning objective, which is obesity is a chronic progressive disease.
- 1:48SPEAKER_00: What should clinicians know and understand about that one statement when it refers to obesity?
- 1:55SPEAKER_01: I think that that it's a it's a really important topic because obesity for many, many years and decades has really been thought of as some combination of a nutritional disorder, a perhaps a behavioral disorder.
- 2:11SPEAKER_01: And I think that what we now recognize is that uh obesity really is a metabolic disease.
- 2:18SPEAKER_01: A metabolic disease the way we would think about hypertension or diabetes, and it is a chronic disease, meaning that it that you know it's not gonna go away.
- 2:27SPEAKER_01: We're not gonna cure it the way we cure infectious diseases or even cancer.
- 2:31SPEAKER_01: It's really gonna be something that we have to address in a longitudinal way.
- 2:37SPEAKER_01: It has enormous impact, and it has psychological impact, nutritional impact, and the like.
- 2:42SPEAKER_01: But it but it but as we think about it, as we conceptualize it and as we try to address it, particularly with the newer medications that are now available to us, uh, I think we have to recognize that uh our job is to work with a patient to create a therapeutic environment that allows for chronic care.
- 3:02SPEAKER_00: Nice overview, and I agree with you entirely.
- 3:05SPEAKER_00: I want to take one aspect of that chronic progressive disease idea, because we think about disease, we think about pathophysiology and all the obesity complications that arise and so forth.
- 3:16SPEAKER_00: But I want to focus right now on the underlying biology, which relates to appetite dysregulation and metabolic adaptation, the idea of defending the fat mass and why it's so hard for individuals to maintain the lower body weight.
- 3:31SPEAKER_00: And it's not willpower, which I think you're gonna tell us.
- 3:33SPEAKER_00: Help us understand a little bit more what we understand about energy dysregulation and defended fat mass.
- 3:41SPEAKER_01: Well, you know, it's interesting because there's been so much data, and actually a lot of those data that had that were first presented to the scientific world back in the 1970s demonstrated that even in animals, the body regulates how much fat it has.
- 3:58SPEAKER_01: Fat is the energy of the body, it's the gas tank of the human body, uh, how much we have and where we store it.
- 4:06SPEAKER_01: If you think about it, over the course of the lifespan, um, where we store our fat is different.
- 4:12SPEAKER_01: Baby fat is in the upper arms and upper legs, and fat during puberty, particularly as it increases in girls, uh, is uh is more you know distributed, more widely distributed.
- 4:25SPEAKER_01: In pregnancy, there's extra fat, and that is very focused in the in the abdomen and in menopause, if you if you think about menopause, but also also in men, and just in aging, you see that fat is more centrally located and more viscerally located.
- 4:39SPEAKER_01: So the body is doing all that.
- 4:40SPEAKER_01: That's normal, that's without obesity.
- 4:43SPEAKER_01: With obesity, you have a dysregulation of not only how much fat you have, you have too much fat, but you also have a dysregulation of where that fat is.
- 4:53SPEAKER_01: Too much fat in the in the visceral area, fat around the heart, in the liver, in the pancreas, in the kidney.
- 5:00SPEAKER_01: And all of the all of that dysregulation is what makes obesity a disease.
- 5:06SPEAKER_01: The problem is that the dysregulation, if you think about it like a thermostat, the dysregulation is the wrong setting of the thermostat.
- 5:14SPEAKER_01: But even if you set the thermostat in your house wrong, what happens is your heating system and your air conditioning system will defend that wrong setting.
- 5:24SPEAKER_01: So if you set your your the temperature of your house in the winter to 50 degrees, what's going to happen is your system is going to protect 50 degrees.
- 5:32SPEAKER_01: Well, the body does exactly the same thing.
- 5:34SPEAKER_01: And so the protection of the right amount of fat is intact.
- 5:41SPEAKER_01: The setting of the right amount of fat, and in this case, different from the thermostat, the location of that fat is what is misrepresented in obesity.
- 5:51SPEAKER_01: So what you have to do is we have to figure out how to how to solve that problem.
- 5:56SPEAKER_01: And it's been incredibly difficult because it's such a complicated disease.
- 6:00SPEAKER_01: The biology is mostly in the brain.
- 6:02SPEAKER_01: It's incredibly complicated.
- 6:04SPEAKER_01: Uh, and so what we've learned is if you all you do is overeat if that's what you want to do as a movie actor, or undereat if that's what you want to do to uh to uh lose weight permanently, it becomes very difficult if all you do is decrease the number of calories.
- 6:19SPEAKER_01: So it turns out it's not about calories.
- 6:21SPEAKER_01: It may it's a lot about what you eat, because what you eat influences the regulatory system, but it's not about how much you eat.
- 6:29SPEAKER_01: That gets determined by the regulatory system.
- 6:31SPEAKER_01: And so we have to fix the regulatory system, we have to fix that uh in any way we can, and then we end up with a good result that we're beginning to see clinically.
- 6:41SPEAKER_00: Great analogy with a thermostat.
- 6:43SPEAKER_00: I think that's gonna resonate with uh all of the listeners, um, and and re and we need to reset it, which really kind of brings me the direction I want to go, and that is we've learned to reset it with one with bariatric surgery, which is not the topic we're talking about today, but with pharmacotherapy.
- 7:00SPEAKER_00: And I want to step back a little bit on how we've treated obesity and how it's evolving.
- 7:04SPEAKER_00: For reasons not clear to me, Lee, uh we we we think about obesity like one drug, and if it doesn't work, we go to another drug.
- 7:11SPEAKER_00: It's kind of monotherapy.
- 7:13SPEAKER_00: And that is not at all how we treat things like hypertension, diabetes, and so forth, or we use multiple drugs.
- 7:20SPEAKER_00: Why do you think we started that way and where is the direction going regarding treating obesity like another chronic progressive disease when it comes to pharmacotherapy?
- 7:58SPEAKER_01: This is such an important point.
- 8:00SPEAKER_01: Uh the I like to describe it as uh the anti-robert frost.
- 8:06SPEAKER_01: Now, what do you what am I talking about when I talk about the anti-robert frost?
- 8:10SPEAKER_01: He wrote a poem about uh the road not taken, and he was saying I I took the road not taken, and that made all the difference.
- 8:18SPEAKER_01: In obesity, we absolutely want to take the road taken.
- 8:22SPEAKER_01: We want to take the road that we use for every other disease.
- 8:26SPEAKER_01: And when you say that we don't do it in obesity in terms of using accommodation therapies, that's the mistake.
- 8:32SPEAKER_01: That's not the, that's that's that's a mistake because we don't think of obesity.
- 8:36SPEAKER_01: We don't talk about obesity when we talk about other diseases, and so the world doesn't understand it that way.
- 8:42SPEAKER_01: But what we do, as you pointed out, for hypertension, for dyslipidemia, for diabetes, for chronic inflammatory diseases, really for almost every kind of disease, cancer, and even infectious diseases, if one drug doesn't work for whatever reason, we either add a drug or we switch to a different drug.
- 9:00SPEAKER_01: Switching to a different drug is perfectly fine, but we keep in our minds that when you have drugs of different mechanisms, they can complement each other.
- 9:09SPEAKER_01: And we know that all of the therapies for obesity have a very uh uh broad spectrum of activity in individual patients, meaning in some patients they cause a lot of weight loss and a lot of improvement and complications, and in other patients they don't do as well.
- 9:25SPEAKER_01: And so because of that heterogeneity of response, we have a choice.
- 9:30SPEAKER_01: We can either say the drug didn't work and we go to a different drug, or we can say maybe two different mechanisms together can complement each other.
- 9:38SPEAKER_01: And everybody knows how to do that.
- 9:40SPEAKER_01: The road taken is that everybody knows how to do that for all the other diseases, so we just have to apply it to obesity.
- 9:46SPEAKER_00: Yeah, well, well said.
- 9:48SPEAKER_00: I I want to pick up on complementary action.
- 9:50SPEAKER_00: I think clinicians know that, right?
- 9:52SPEAKER_00: Diabetes is not well controlled.
- 9:53SPEAKER_00: Let's take another medication and may complement that, although potentially different mechanisms of action.
- 10:00SPEAKER_00: And I think, and you agree, we're right on the cusp of that with these nutrient-stimulated hormone-based therapeutics.
- 10:06SPEAKER_00: We have more gut hormones, and they can have complementary action or perhaps potentially synergistic action or diverse action.
- 10:14SPEAKER_00: So I wonder if you could separate that out a little bit and how you think, in particular, amylen may actually uh uh participate in that.
- 10:22SPEAKER_01: So I'm gonna use an example of amylin with diabetes as a way to answer the question.
- 10:28SPEAKER_01: When you stimulate the pancreas, the pancreatic beta cells, with a drug or a therapy like GLP1 receptor agonist, the GLP1 receptor agonist acts as an incritin, and the incritin stimulates the pancreatic beta cell to secrete insulin under conditions where you have enough glucose in your blood, of course, but but it causes a secretion of insulin.
- 10:51SPEAKER_01: But in those same granules where insulin is being secreted, amylin is always there and it's always being secreted.
- 10:58SPEAKER_01: So for diabetes, and this is only for diabetes, it turns out that when you use an incritin, you're also stimulating amylene.
- 11:07SPEAKER_01: So you have to ask the question: is amylen really complementary to insulin, or is it just part of the same pathway and it may or may not be complementary?
- 11:14SPEAKER_01: There could be additional sources of amylene that that would would be helpful, independent of what the GLP1 does.
- 11:23SPEAKER_01: But it could also be that amylen is just is just a way of goosing up GLP1.
- 11:29SPEAKER_01: In obesity, it's a completely different situation.
- 11:32SPEAKER_01: The effects that we're talking about are not effects on the pancreas directly, but effects on the brain.
- 11:38SPEAKER_01: And because they're effects on the brain, we don't know the wiring diagram.
- 11:41SPEAKER_01: We don't know that the neurons in the brain that respond to GLP1 have anything to do with amylin.
- 11:47SPEAKER_01: We just simply don't know.
- 11:48SPEAKER_01: So what we have to think about when we put two different drugs together is if they're in the same pathway, the second drug might just be goosing up the first drug.
- 11:59SPEAKER_01: If they're in different pathways, the second drug might be complementary.
- 12:04SPEAKER_01: How does that benefit the patient?
- 12:07SPEAKER_01: So let's talk about the clinical aspects of that.
- 12:10SPEAKER_01: Well, if you're goosing it up, what you're doing is you're saying you get that drug and you give amylin, what you could be doing is you could just simply doubling the efficacy.
- 12:19SPEAKER_01: Okay, so you're so if you don't do well with the with the with the first drug, you still double the efficacy.
- 12:26SPEAKER_01: But if you do really well, you double the efficacy because all you're doing is goosing up the system.
- 12:30SPEAKER_01: You sort of like you're you're turning up the gain on the oscilloscope.
- 12:35SPEAKER_01: On the other hand, if they're truly complementary, what you can see is that somebody who doesn't respond very well to the first drug might respond very well to the amelin because it's different mechanisms and they're complementary.
- 12:48SPEAKER_01: You could have a type of obesity that just simply doesn't respond well to a GLP1 and now suddenly responds very well when you give it an amelin.
- 12:57SPEAKER_01: And so when you take the whole population, by having both drugs available to you, you can take all the people who didn't respond, and maybe they'll respond to the second drug, but it may, and they may even respond better to the second drug than they than the average, even though they responded worse than the average to the first drug.
- 13:14SPEAKER_01: That's true complementarity, and that's true synergy or has the potential for true synergy.
- 13:20SPEAKER_01: We don't yet know in obesity when we add a second mechanism whether we're goosing up the system or whether we are truly being complementary.
- 13:29SPEAKER_01: But either way, we're benefiting the patient.
- 13:32SPEAKER_01: So either way, we ought to be exploring that.
- 13:35SPEAKER_01: And once again, coming back to what we talked about earlier, that's exactly what we do with almost every other chronic disease that we treat.
- 13:42SPEAKER_01: Why we haven't done it in obesity, I think is just a sort of a lacoon in our thinking.
- 13:46SPEAKER_01: It's just a it's a it's a gap that we need to fill.
- 13:50SPEAKER_00: Yeah, thanks.
- 13:51SPEAKER_00: I think that's going to resonate with clinicians, because as you already said, just to reiterate this, when we treat other chronic diseases, we think about adding another medication for complementary reasons, uh, increasing diversity of outcome or non-response or poor response.
- 14:06SPEAKER_00: Let me stick with this heterogeneity of treatment response.
- 14:09SPEAKER_00: All clinicians know that, right?
- 14:10SPEAKER_00: We we see patients obviously say, well, on average, this is what we look for, but there's a big variety here.
- 14:16SPEAKER_00: Help us understand our current thinking about this heterogeneity of response.
- 14:21SPEAKER_00: We have super responders as clinicians, right?
- 14:23SPEAKER_00: So people where we slow down the weight loss, and those that are very frustratingly and disappointingly do not have much of a response.
- 14:30SPEAKER_00: What do we understand about that also when it comes to thinking of phenotypes in this case?
- 14:36SPEAKER_00: What do we think is going on here?
- 14:40SPEAKER_01: So so I think what we've learned from genetic studies, I won't get into the details of that, but what we've learned from genetic studies so far is that the best therapies for obesity don't reverse the underlying cause of obesity.
- 14:57SPEAKER_01: What they do is they work through a different pathway.
- 14:59SPEAKER_01: How do we know this?
- 15:00SPEAKER_01: Because the genetics of obesity are not the same as the genetics of response to these therapies.
- 15:05SPEAKER_01: And the therapies I'm talking about are the drug therapies and bariatric surgery.
- 15:10SPEAKER_01: I'm not I'm not getting into the uh lifestyle-based therapies in this discussion.
- 15:14SPEAKER_01: So what it means is that what you're doing is you're treating the disease.
- 15:19SPEAKER_01: You found a target, such as GLP1, that isn't the cause of obesity, because if you knock out GLP1 or its receptor, you don't get obesity.
- 15:28SPEAKER_01: So therefore, GLP1 isn't necessary for the system to regulate your weight correctly, but it's a very effective target for overcoming whatever the cause, the original cause of obesity is.
- 15:41SPEAKER_01: So why is that important?
- 15:42SPEAKER_01: Why do we differentiate that?
- 15:44SPEAKER_01: Because what it means is that there could be lots of different causes for obesity.
- 15:49SPEAKER_01: Some people respond to uh stress by developing obesity, other people respond to certain diets, say a highly processed diet.
- 15:56SPEAKER_01: But not everybody does that by developing obesity.
- 16:00SPEAKER_01: But when you have a therapy that's as effective as the therapies that we've recently seen uh come forward, you know, the uh pharmacological therapies, they work through specific pathways.
- 16:13SPEAKER_01: But one kind of obesity might not work as might not respond as well as another kind of obesity, and we don't really know what the kinds of obesity are.
- 16:20SPEAKER_01: We don't know those pathways in the brain that are that are missetting that obesity thermostat or that lipostat.
- 16:27SPEAKER_01: Uh so, but it could be very different.
- 16:30SPEAKER_01: And we know it's different because people develop obesity under different conditions.
- 16:35SPEAKER_01: We that already we know.
- 16:37SPEAKER_01: And we also know that they respond very variably to any therapy, including bariatric surgery, including a a healthy lifestyle, including stress reduction, they respond very differently from person to person.
- 16:49SPEAKER_01: So when you put all that together, wouldn't it be nice to know who in advance who is going to respond to which therapy?
- 16:57SPEAKER_01: And when you, if you did know that in advance, you could then target that person to that therapy.
- 17:01SPEAKER_01: And for other diseases, we often know that.
- 17:03SPEAKER_01: Sometimes we have genetic markers, sometimes we have biomarkers, sometimes we just have clinical markers.
- 17:08SPEAKER_01: In obesity, we have none of that.
- 17:10SPEAKER_01: Now, I think that in the future we will have that.
- 17:13SPEAKER_01: And I think the work about uh different phenotypes, particularly uh appetitive appetite-related phenotypes, is going to be an interesting place to start.
- 17:23SPEAKER_01: Whatever it is, what we need is any kind of clue that will say we can be more efficient with the care of every patient by knowing something special about the phenotype of that patient.
- 17:35SPEAKER_01: And I think that's the future of obesity care.
- 17:37SPEAKER_00: Yeah, that's unfortunately missing.
- 17:39SPEAKER_00: As you know, all we have is what we call process indicators.
- 17:42SPEAKER_00: And that is, well, let's start Jan Symagulatine, we'll see how you do, right?
- 17:47SPEAKER_00: What that weight trajectory looks like and so on.
- 17:49SPEAKER_00: So we have to start the treatment before we know.
- 17:51SPEAKER_00: We don't have anticipatory uh predictors yet, as you just said, who are heading to.
- 17:57SPEAKER_01: We have, you're absolutely right, but we have something that we've never had before.
- 18:02SPEAKER_01: We have drugs with multiple mechanisms.
- 18:05SPEAKER_01: The first one that we know about is GLP1, but then GIP was added in terzepitide, and glucagon has been added in retitruti and in in servodutide.
- 18:17SPEAKER_01: Um now we're talking about amylene, and amylene is a completely independent predictor.
- 18:22SPEAKER_01: And of course, there are others that are being explored: NPY, PYY receptor agonists, and and many others.
- 18:31SPEAKER_01: So, what it does is it gives us at least the possibility when somebody doesn't do as well as we would like or they would like in responding to the therapy to try something else.
- 18:42SPEAKER_01: Yes, it's hit and miss, it's trial and error.
- 18:45SPEAKER_01: But you know, for most diseases, it starts as trial and error.
- 18:48SPEAKER_01: You don't always know your mechanisms before you start good therapy.
- 18:52SPEAKER_01: And in this case, we don't yet know exactly what the best pathway is, which drug we should use first, which one we should use second, and which patients.
- 19:02SPEAKER_01: But even we don't know in advance the right drug for the right patient at the right time, we have a way because you can stop and start drugs, change the dose, add them together in different combinations, and that's what we do.
- 19:15SPEAKER_01: Coming back to it, that's the path taken, that's the path we should take for obesity.
- 19:48SPEAKER_00: And there's another concept I think I just want to draw out, which may be obviously as well as to the clinicians, is I think the direction we're going in obesity is not to push one nutrient-stimulated hormone therapeutics to the max, right?
- 20:01SPEAKER_00: We talk about max well-tolerated dose, right?
- 20:03SPEAKER_00: And then complementary add another drug too.
- 20:07SPEAKER_00: Then I think we're going in the same direction, right?
- 20:09SPEAKER_00: So we may end up in the future where, depending on someone's uh risk status and number and severity of obesity-related complications, could be on one or two, or even three, perhaps, right, nutrient-stimulated hormone-based compounds, either individual drugs or as single molecules, rather than pushing one all the way uh to the maximum.
- 20:31SPEAKER_01: This is such an important point that you raise, and I think that that uh it needs to be emphasized.
- 20:38SPEAKER_01: There are two benefits to taking, let's just say, two drug combinations, but we have, of course, in hypertension and other diseases, three and four drug combinations.
- 20:46SPEAKER_01: But the the let's just look at any two drug combination.
- 20:50SPEAKER_01: There's two ways to look at it.
- 20:52SPEAKER_01: One is to say, one drug isn't good enough, so I've got to add a second drug.
- 20:55SPEAKER_01: Even if at maximum dose of the first drug, it's not doing the job that we need to have it do, and so we use a second drug.
- 21:02SPEAKER_01: But every drug, there isn't a single drug in the in the pharmacopoeia that doesn't have side effects to some degree.
- 21:08SPEAKER_01: And so what the other benefit is you can use lower doses of two drugs, save yourself or save the patient from having adverse effects, but still get the same benefit.
- 21:21SPEAKER_01: So a lower dose, I just pick two of a lower dose of a GIP and a lower dose of a GLP1, or a lower dose of an amylin and a lower dose of a GLP1, could give you the same benefit as a higher dose of either one.
- 21:37SPEAKER_01: But if it does so at a lower risk to the patient, at a lower likelihood of intolerance to the patient, that's a better clinical outcome for that patient.
- 21:46SPEAKER_01: At the same time, of course, let's not forget that for other diseases, we don't start with maximally tolerated dose.
- 21:54SPEAKER_01: The only diseases where we start with maximally tolerated dose frequently are diseases where we're trying to kill something.
- 22:00SPEAKER_01: So that's infectious diseases and cancer, where you want to give them a big hit early on in order to kill the offending uh cell or organism.
- 22:09SPEAKER_01: But in most chronic diseases, we start with the lowest effective dose, and we have two opportunities.
- 22:17SPEAKER_01: Do you work up from the lowest effective dose or do you complement the lowest effective dose or an intermediate dose with a different drug?
- 22:26SPEAKER_01: And I think that our experience and the experience of every clinician who's active in practice is the same, which is you do whatever the patient needs and you tolerate and you and you and you use the therapy that's right for that patient.
- 22:41SPEAKER_01: We haven't had the opportunity to do that before with effective drugs and obesity.
- 22:44SPEAKER_01: We now have that opportunity.
- 22:46SPEAKER_01: We now have multiple mechanisms, and I think with that over the next few years, we're going to learn how to use those multiple mechanisms to the benefit of all of our patients.
- 22:55SPEAKER_00: Yep.
- 22:55SPEAKER_00: Person-centered care.
- 22:57SPEAKER_00: That's exactly what we're heading towards.
- 22:58SPEAKER_00: Lee, as we as we close out this snack, and for all the clinicians who are watching and listening today, what's the one shift in thinking you want them to take back to the clinic, even before we have more confirmatory data regarding amylin and some of the other nutrient-stimulated based hormones, therapeutics?
- 23:17SPEAKER_01: I think the one thing I would say is that we are going to be having, there are more than 120 drugs in development right now.
- 23:23SPEAKER_01: So we're going to have a lot of choices.
- 23:25SPEAKER_01: We're going to have to figure out, you know, try to figure out who would both most benefit from all these new drugs.
- 23:32SPEAKER_01: Just because you have another GLP1 doesn't mean either that it's going to be better or that it's going to be useless because we already have GLP1s.
- 23:40SPEAKER_01: We don't know.
- 23:41SPEAKER_01: There are different kinds of GLP1s.
- 23:43SPEAKER_01: There are different kinds of GIP agonists, and there are different kinds, quite a number of different kinds of amylin agonists.
- 23:51SPEAKER_01: Ones that are that are biased and unbiased, ones that are DACR, they activate, uh they activate calcitonin or they don't activate.
- 23:59SPEAKER_01: They activate the amylen 1 receptor or the amyline 2 receptor or both receptors.
- 24:03SPEAKER_01: So you have all kinds of different things.
- 24:05SPEAKER_01: And I think that that if we if we remember one thing as we move forward, it's that in every other disease, we've used the the diversity of drugs.
- 24:18SPEAKER_01: Think about uh alpha versus beta agonists and antagonists.
- 24:25SPEAKER_01: Think about beta 1 versus beta 2 later that came later on.
- 24:29SPEAKER_01: Think about combinations of alpha and beta that you have with libetolol.
- 24:33SPEAKER_01: This all came as a normal developmental process in the case of beta-adrenergic signaling.
- 24:40SPEAKER_01: Well, now we have new kinds of signaling that are relevant to obesity, and we're going to see the same pathway.
- 24:45SPEAKER_01: And our minds should be open to using using, trying, evaluating more and more approaches, even if some of the mechanisms overlap, and then of course complementing the mechanisms with ones that don't overlap.
- 25:01SPEAKER_00: Thank you.